Proprio

Executive Summary

Proprio is a Seattle-based medtech company founded in 2016 that is transforming surgical precision through its FDA-cleared Paradigm™ platform. By integrating advanced sensors, computer vision, and artificial intelligence, Paradigm generates real-time 3D anatomical models during procedures, enhancing accuracy and streamlining surgical workflows. The platform's ability to capture structured data enables continuous learning and improvement across the surgical care continuum, positioning Proprio at the intersection of AI, medical devices, and neurosurgery. With its first product already cleared by the FDA, Proprio is poised to disrupt the surgical navigation market, which is currently dominated by legacy systems. The company's focus on data-driven insights and workflow efficiency could reduce operative times and improve patient outcomes, driving adoption in neurosurgery and potentially expanding into other surgical specialties. However, as a private, pre-revenue (likely) startup, Proprio faces challenges in commercialization, regulatory expansion, and securing funding to scale. Its success will depend on clinical validation, strategic partnerships, and capital raises.

Upcoming Catalysts (preview)

• Q4 2026Series B or Later Funding Round75% success
• Q1 2027FDA Clearance for New Surgical Indications (e.g., Spine)60% success
• Q3 2026Publication of Key Clinical Data or Partnership Announcement55% success